Only one study identified a relatively high frequency of BRAF mutations in endometrial cancers (21%), with an apparent overrepresentation in MLH1-deficient tumors (41% vs. 11% in pMMR tumors) [273]. The gene discussed is BRAF; the disease is endometrial cancer.